Treatment options for persons with leukemia relapsing after allogeneic transplantation are limited. We analyzed the outcome of 279 patients with acute and chronic leukemia, who relapsed after HLA-identical sibling transplantation and received a second allogeneic transplant. The influence of potential risk factors on treatment-related mortality (TRM), relapse, treatment failure (relapse or death) and overall survival after second transplantation were assessed using proportional-hazards regression. The cumulative incidences (95% confidence interval) of relapse and TRM at 5 years were 42 (36-48)% and 30 (24-36)%, respectively. The 5-year probabilities of both overall and leukemia-free survival were 28 (23-34)%. In multivariate analyses, risks of treatment failure and mortality were lower in younger patients (p20 years) and patients who relapsed after 6 months from first transplantation. Risks of relapse were lower in patients who relapsed after 6 months from first transplantation and in complete remission prior to second transplantation. Risks of relapse were higher after reduced-intensity conditioning regimens. Any potential advantage of using a different matched related donor for a second transplantation is not supported by these data. Although age, disease status and conditioning regimen are important, duration of remission after first transplantation appear to be the most important determinant of outcome.
Summary:
Treatment options for persons with leukemia relapsing after allogeneic transplantation are limited. We analyzed the outcome of 279 patients with acute and chronic leukemia, who relapsed after HLA-identical sibling transplantation and received a second allogeneic transplant. The influence of potential risk factors on treatment-related mortality (TRM), relapse, treatment failure (relapse or death) and overall survival after second transplantation were assessed using proportional-hazards regression. The cumulative incidences (95% confidence interval) of relapse and TRM at 5 years were 42 (36-48)% and 30 (24-36)%, respectively. The 5-year probabilities of both overall and leukemia-free survival were 28 (23-34)%. In multivariate analyses, risks of treatment failure and mortality were lower in younger patients (p20 years) and patients who relapsed after 6 months from first transplantation. Risks of relapse were lower in patients who relapsed after 6 months from first transplantation and in complete remission prior to second transplantation. Risks of relapse were higher after reduced-intensity conditioning regimens. Any potential advantage of using a different matched related donor for a second transplantation is not supported by these data. Although age, disease status and conditioning regimen are important, duration of remission after first transplantation appear to be the most important determinant of outcome. Leukemia recurs in 20-70% of persons after allogeneic transplantation, with risk of recurrence depending primarily on the type of leukemia and disease status at transplantation. [1] [2] [3] Prognosis of patients who relapse is poor and an optimal salvage therapy has yet to be established. Current treatment options include chemotherapy, donor leukocyte infusions (DLI) and second allogeneic transplantation. Intensive chemotherapeutic regimens can induce remission in some patients with recurrent leukemia, but remission durations are short, and most patients die of uncontrolled leukemia or infectious complications. DLI results in durable clinical and molecular remission in chronic myelogenous leukemia (CML), especially when used for early disease. [4] [5] [6] [7] [8] [9] Results of DLI for acute leukemia relapsing after allogeneic transplantation are less encouraging; only 10-20% of patients achieve complete remission (CR) and remissions are usually brief. 6, 10, 11 Moreover, acute and chronic graft-versus-host disease (GVHD) and infections from marrow aplasia and/or immunosuppressive therapy after DLI are associated with substantial morbidity and mortality. 4, 9, 11 A new therapy for CML is imatinib mesylate, a tyrosine kinase inhibitor. In the short term, imatinib may be used successfully to induce and maintain remission in CML recurring after allogeneic transplantation. 12 However, follow-up of imatinib-treated patients is short and further studies are required to document durability of remissions.
Second allogeneic transplantation may be effective salvage therapy in some patients who relapse after an initial transplant. 1, 3, [13] [14] [15] [16] [17] [18] [19] [20] [21] Thus far, most studies of second transplants for recurrent leukemia are limited by small numbers of patients with heterogeneous prognostic factors. While early relapse after first transplantation and advanced disease status at second transplantation predict poor outcome, data on other factors that may affect outcomes such as conditioning regimen and use of a different donor are few. To better identify risk factors that influence outcome, we studied 279 recipients of second transplants from an HLA-identical sibling donor for leukemia recurring after initial HLA-identical sibling transplantation and reported to the International Bone Marrow Transplant Registry (IBMTR).
Methods

Data collection
Data on patients undergoing second allogeneic transplantation were obtained from the Statistical Center of the IBMTR. The IBMTR is a voluntary working group of over 400 transplant teams worldwide that contribute detailed information on their allogeneic transplants to a Statistical Center at the Medical College of Wisconsin. Participating centers are required to register all consecutive transplant recipients. The IBMTR database includes information on 40-45% of allogeneic transplants performed worldwide since 1970. Transplant recipients are followed longitudinally. Computerized error checks, physician review of submitted data, and on-site audits of participating centers ensure data quality.
Inclusion criteria
The study includes patients, with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML) or CML, who received a second allograft from an HLAidentical sibling for recurrent or persistent leukemia after initial HLA-identical sibling transplantation, and transplanted between January 1, 1990 and December 31, 2000. In all, 279 patients fulfilled the eligibility criteria (Table 1) . Data from the IBMTR suggest that approximately 6% of patients, with recurrent leukemia after a first matched related donor transplant receive a second matched related donor transplant using the same or a different donor. Patients who received DLI for recurrent leukemia after their initial transplant were excluded. Transplant teams reporting to the IBMTR are requested to indicate whether patients received a blood or marrow infusion as a second or subsequent transplant, or DLI. Inconsistencies are resolved by either a data manger or physician at the transplant center.
End points
The study examined hematologic recovery, acute and chronic GVHD, treatment-related mortality (TRM), relapse, leukemia-free survival (LFS), treatment failure (relapse or death, inverse of LFS) and overall survival after second allogeneic transplantation for recurrent leukemia. The outcome data were compiled from the date of second transplantation to date of last contact or death. Hematopoietic recovery was defined as achieving an absolute neutrophil count (ANC) X500/ml and platelets X20 000/ml. The incidence of grades 2-4 acute GVHD was evaluated in all patients; 22, 23 chronic GVHD was evaluated in patients surviving 90 days or longer after second transplant. 24 TRM was defined as death in continuous remission; patients were censored at relapse or, for those in clinical remission, at last follow-up. Relapse was defined as hematologic recurrence for both acute and chronic Cy ¼ cyclophosphamide; Ara-C ¼ cytosine arabinoside. a Reduced intensity conditioning regimens were defined as: any fludarabinecontaining regimen; TBIo400 cGy7other agents; melphalan p150 mg/ m 2 7Ara-C/etoposide; cyclophosphamide7Ara-C; busulfan p12 mg/ kg7Ara-C/etoposide; high-dose Ara-C7etoposide.
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Statistical analysis
Probabilities of LFS and overall survival were calculated using the Kaplan-Meier estimator. 25 Cumulative incidence rates (the chance a patient will have experienced a particular competing risk prior to time t, and where death without an event is the competing risk) were calculated using standard techniques for hematopoietic recovery, acute and chronic GVHD, TRM and relapse. 25 The standard error of the survivor function by Greenwood formula was used to calculate the 95% confidence intervals (CI). 25 Potential prognostic factors for TRM, relapse, treatment failure and overall mortality were evaluated in multivariate analyses using Cox proportional-hazards regression. 26 Multivariate models were built using a stepwise forward selection with a significance level of 0.05. Variables considered in multivariate analyses are shown in Table 2 . Whenever categories of variables initially classified into more than two categories showed no statistically significant differences between categories, categories were collapsed to create the fewest possible number groups (such as: age and duration of remission after first transplant). In each model, the assumption of proportional hazards was tested for each variable using a time-dependent covariate. First-order interactions between variables were examined by fitting a proportional-hazards model and examining interaction between variables. Associations between GVHD and leukemia recurrence after transplantation were tested by modeling acute and chronic GVHD as time-dependent covariates with other significant variables in the final multivariate model for relapse. All multivariate models were examined for center effects by using random effects or frailty model; 27 there was no evidence of confounding by center effects. Completeness of follow-up was assessed using a C statistic, which gives a measure of the proportion of all potential follow-up information available for this study. 28 All P-values are two-sided. All analyses were carried out using PROC PHREG in SAS version 8.0 (SAS Institute Inc., Cary, NC, USA).
Results
Patient and transplant characteristics
Patient, disease and transplant characteristics at first and second transplantation are presented in Table 1 . All patients received allografts from HLA-identical sibling donors; 85% received allografts from the same donor for both transplants. Graft type, conditioning regimen and GVHD prophylaxis were determined by transplant teams. In all, 90% of second transplants for recurrent CML were between 1990 and 1994. Bone marrow was the most common graft type. No patient received an irradiation containing conditioning regimen for both transplants, and 16% received a reduced-intensity conditioning regimen for their second transplant. The median follow-up of survivors is 93 (range 6-147) months and the completeness of followup is 90%. 27 A total of 90% of survivors were followed for at least 2 years after second transplantation.
Hematopoietic recovery
Most patients achieved hematopoietic recovery. The median times to neutrophil and platelet recovery were 16 (range, 6-82) days and 23 (8-364) days, respectively. The cumulative incidences (95% CI) of achieving ANC X500/ml at day 100 and platelets X20 000/ml at 1 year were 86 (77-92)% and 83 (72-90)%, respectively.
Acute and chronic GVHD
The cumulative incidence of grade 2-4 acute GVHD at day 100 was 29 (24-35)%. The cumulative incidences of chronic GVHD at 1 and 5 years were 39 (31-46)% and 41 (33-48)%, respectively. T-cell depletion for first transplantation or not having received GVHD prophylaxis for the second was not associated with outcomes after second transplantation. To further examine the association, if any, Outcomes after second allogeneic transplantation M Eapen et al with GVHD prophylaxis at second transplantation and outcome, we created four categories: same donor, same GVHD prophylaxis for both transplants, same donor, different GVHD prophylaxis for both transplants, different donor, same GVHD prophylaxis for both transplants and different donor, different GVHD prophylaxis for both transplants. During model building, this did not attain a significance level of 0.05. Nevertheless, this was forced into the final model for TRM, relapse, treatment failure and overall survival, and we did not observe an association. Among patients who did not develop acute GVHD after first transplantation, rates of acute GVHD after second transplantation with the same or a different donor were 29% and 26%, respectively. In contrast, patients who received allografts from the same donor for both transplants and developed grade 2-4 acute GVHD after their first transplant were more likely to develop grade 2-4 acute GVHD after their second, relative risk (RR) 1.74, 95% CI 1.02-2.96, P ¼ 0.04. A similar trend was not observed among patients who developed acute GVHD after first transplant, but received the graft from a different donor for the second transplant. Chronic GVHD was more likely after second transplant in patients who received their allograft from a different donor rather than from the same donor for both transplants (61 vs 37%, P ¼ 0.03), but this did not translate into a survival advantage (39 vs 28%, P ¼ 0.2).
Treatment-related mortality
Risks of TRM were higher in patients older than 20 years of age and in those who relapsed p6 months after their first transplant ( Table 3 ). The cumulative incidences of TRM at 1 and 5 years were 26 (21-31)% and 30 (24-36)%, respectively (Figure 1) . The 1-year cumulative incidence of Table 3 Factors associated with outcomes after second transplantation Outcomes after second allogeneic transplantation M Eapen et al TRM in patients with neither of these risk factors (n ¼ 71) was 20 (12-30)%; in patients with both risk factors (n ¼ 36), the cumulative incidence was 25 (14-38)%.
Relapse
The cumulative incidences of relapse at 1 and 5 years were 36 (31-42)% and 42 (36-48)%, respectively (Figure 1 ). Risk of relapse was higher in patients with a short (p6 months) remission after first transplant, those who were not in CR at second transplant and those who received reducedintensity conditioning (Table 3) . Grade 2-4 acute GVHD after second transplant was associated with lower risk of relapse, RR 0.50, 95% CI 0.27-0.93, P ¼ 0.03. Risk of relapse was similar in patients with and without chronic GVHD after second transplant.
Treatment failure
Probabilities of LFS at 1 and 5 years were 38 (32-43)% and 28 (23-34)%, respectively. Risk of treatment failure was higher in patients older than 20 years of age, in those who relapsed p6 months after their first transplant and in those not in CR at second transplantation (Table 3) . Among patients with none of these risk factors (n ¼ 71), the 5-year probability of LFS was 49 (36-60)%; among those with all these risk factors (n ¼ 36), the probability was 3 (0.02-12)% ( Figure 2 ).
Overall survival
Probabilities of overall survival at 1 and 5 years were 41 (35-46)% and 28 (23-34)%, respectively. Risk of mortality was higher in patients older than 20 years of age and in those who relapsed p6 months after their first transplant (Table 3) . Among patients with neither of these risk factors (n ¼ 71), the 5-year probability of overall survival was 51 (38-62)%; among those with both risk factors (n ¼ 36), the probability was 3 (0.02-12)% (Figure 3) . Disease status at transplantation was not associated with overall mortality, RR 1.26, 95% CI 0.94-1.69, P ¼ 0.12.
In total, 202 patients (72%) died. Recurrent leukemia (58%) was the most frequently reported primary cause of death. Other reported causes included GVHD (11%), interstitial pneumonitis (12%), infections (9%), organ failure (5%), second malignant neoplasm (1%) and other causes (4%). The median (range) time from second transplantation to death was 4 (o1-100) months.
Discussion
A second allogeneic transplant for leukemia recurring after first transplant may be a reasonable treatment option in selected patients. However, identification of factors influencing relapse and mortality after second transplantation and determination of patient groups who best respond to this therapy have proven difficult. Using data from the IBMTR, Mrsic et al 1 reported outcomes in 114 recipients of second HLA-identical sibling transplants between 1978 and 1989. In their study, relapse occurring later than 6 months after first transplant, diagnosis of CML and CR at second transplant were associated with a better outcome. The primary objective of the current study was to identify potential risk factors in a more contemporary period. We found length of remission after first transplant, and age, disease status and conditioning regimen at second trans- years, duration of remission 46 months and in CR; (B) age p20 years, duration of remission 46 months and not in CR; (C) age 420 years, duration of remission 46 months and in CR; (D) age 420 years, duration of remission 46 months and not in CR; (E) age p20 years, duration of remission p6 months and in CR; (F) age p20 years, duration of remission p6 months and not in CR; (G) age 420 years, duration of remission p6 months and in CR; and (H) age 420 years, duration of remission p6 months and not in CR. Age p20 years, duration of remission 46 months; (B) age 420 years, duration of remission 46 months; (C) age p20 years, duration of remission p6 months; and (D) age 420 years, duration of remission p6 months.
Outcomes after second allogeneic transplantation M Eapen et al plant to be important in determining outcomes after second transplant. Although acute GVHD after second transplant correlated with a lower risk of relapse, we found no evidence to support the use of a different matched related donor to increase the likelihood of developing GVHD after second transplantation. Our data, as well as other reports, indicate that length of remission after first transplantation is probably the most important variable predicting outcome after second transplant. 1, 3, 15, [17] [18] [19] [20] [21] Relapse, treatment failure and mortality are higher in patients with early relapse. We defined early relapse as occurring within 6 months after first transplant. Interestingly, we observed similar outcomes for patients who relapsed 7-12 months and those who relapsed later after their first transplant. This contrasts with other recent reports suggesting better outcomes in patients relapsing in the first year after transplantation. 3, 20, 21 Similar to other reports, we did not observe a correlation between interval from relapse to second transplant and treatment failure or mortality. 1, 3, 17, 20 As expected, patients with active leukemia at transplant were also less likely to do well, similar to other reports. 1, 3, 19, 20 Age correlated with TRM, treatment failure and overall mortality, probably the result of better tolerance of therapy in younger patients. Factors generally accepted as predicting outcomes after first transplant, such as duration of pretransplant remission for acute leukemia, interval from diagnosis to first transplant for chronic leukemia, and disease status at first transplant, did not correlate with the outcome after second transplant. In addition, the specific conditioning or GVHD prophylaxis regimen for first transplant did not seem to predict the outcome of the second transplantation.
In contrast to some reports, outcomes were not different among the three disease groups, ALL, AML and CML. Although the variable for type of leukemia (AML vs ALL vs CML) did not attain a significance level of 0.05, this variable was forced into all final models and the outcomes were unchanged. We defined leukemia relapse as hematological recurrence for both acute and chronic leukemia, and this may explain why we did not observe differences in outcome by type of leukemia. We do not have data on cytogenetics or chimerism, chemosensitive vs refractory disease, and other hematological markers such as the percent of circulating blasts, and platelet count at relapse after first transplantation. While these factors may be of prognostic significance, we were unable to examine their prognostic significance in this data set and acknowledge this as one of the limitations of a registrybased study.
Most transplant strategies rely heavily on maximally tolerated doses of chemotherapy, with or without radiation, to eradicate cancer, and allografts to rescue patients from therapy-induced marrow aplasia as well as to provide immune-mediated effects. Some reports suggest that conditioning regimens with total body irradiation (TBI) may lower mortality in patients with acute leukemia after second transplantation. 3 We did not observe this. Only a third of patients in this study received a TBI-containing regimen and AML was the most common disease in this group. Most patients with ALL and CML received a TBIcontaining regimen for their first transplant. More recently, reduced-intensity conditioning regimens and postgrafting immunosuppression to control graft rejection and GVHD have been used to reduce regimen-related toxicities while preserving graft-versus-leukemia (GVL) effects. 29, 30 We found higher rates of relapse after reduced-intensity conditioning. This was independent of the duration of remission after first transplant and disease status at second transplant, suggesting that dose intensity may be important in this setting. These findings should be interpreted with caution due to lack of homogeneity of reduced intensity conditioning regimens, as well as probable biases in patient selection for this relatively new form of therapy.
We found no evidence supporting the use of a different HLA-identical donor for a subsequent transplant. Risks of relapse and mortality were similar whether or not a different donor was used. Using a different matched related donor, when available, for a subsequent transplant to increase the likelihood of GVHD and subsequent GVL effect is not supported by these data. As only 15% of the study population received their second allograft from a different HLA-identical sibling donor, small numbers may have limited our ability to detect differences.
While some studies in adults report survival advantages after peripheral blood stem cell (PBSC) infusion for advanced leukemia, 31,32 others 3 report lower risks of relapse using bone marrow for second transplant. We did not observe a correlation between graft source and risks of relapse or mortality. However, as only 21% of the study cohort received PBSC grafts, small numbers may have limited our ability to detect an effect.
DLI, and more recently, imatinib mesylate have been used successfully to maintain durable clinical and molecular remission in CML. [4] [5] [6] [7] [8] [9] 12 This study population includes patients with CML in hematologic relapse. Although current standard of care for recurrent CML are DLI and/or imatinib mesylate, for those who fail this therapy, a second transplant may be an option. As such, the data presented here may serve as a reference when counseling these patients who have failed DLI and/or imatinib mesylate.
A retrospective report such as ours has limitations such as selection bias for transplantation, choice of conditioning regimen and our inability to adjust for unknown or unmeasured factors that may affect the outcome after transplantation. The data suggest, with a median follow-up of over 7 years, that second allogeneic transplantation produces sustained remission in a proportion of patients. Although disease status, age and conditioning regimen are important, duration of remission after first transplant appears to be the most important determinant of outcome. There seems little point in subjecting patients with posttransplant remission durations of p6 months to a second aggressive procedure. Use of a different matched related donor to improve outcomes after a subsequent transplant is not supported by these data. Further controlled studies are required to define the role of reduced vs standard intensity conditioning regimens in this setting.
